Quick Answer
VYNE Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $570.0 thousand for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +13.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $308.0 thousand | Q2 2019: $0.00 | Q3 2019: $0.00 | Q1 2020: $1.75 million | Q2 2020: $11.69 million | Q3 2020: $3.27 million | Q1 2021: $230.0 thousand | Q2 2021: $295.0 thousand | Q3 2021: $133.0 thousand | Q1 2022: $178.0 thousand | Q2 2022: $126.0 thousand | Q3 2022: $167.0 thousand | Q1 2023: $99.0 thousand | Q2 2023: $135.0 thousand | Q3 2023: $114.0 thousand | Q1 2024: $98.0 thousand | Q2 2024: $198.0 thousand | Q3 2024: $121.0 thousand | Q1 2025: $202.0 thousand | Q2 2025: $69.0 thousand.
- Over the full 8 years of available data (2018 to 2025), VYNE Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 84.1%.
- Historical annual values: Fiscal year 2025: $570.0 thousand | Fiscal year 2024: $501.0 thousand | Fiscal year 2023: $424.0 thousand | Fiscal year 2022: $477.0 thousand | Fiscal year 2021: $931.0 thousand | Fiscal year 2020: $20.99 million | Fiscal year 2019: $443.0 thousand | Fiscal year 2018: $3.60 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: